News

Under the deal, the Irish firm has offered to pay $46 a share for Hyperion, representing a 35% premium to the volume weighted average price for its shares

The deal provides regional packaging capabilities and complements Catalent’s existing facility in Braeside, Victoria, where it produces oral dose products including softgels, Vegicaps capsules, and OptiShell capsules, for

The Irish firm will pay $101 per share to acquire Auspex’s portfolio of new medicines for people who live with movement disorders. The boards of directors from both

Following approval, the new therapy will be marketed under the name Synjardy in Europe. The single-pill therapy is a combination of the sodium glucose cotransporter 2 (SGLT2) inhibitor,

FOLFOX is a combination of the drugs folinic acid, 5-fluorouracil and oxaliplatin. A total of 173 patients were included in the trial, which was conducted at about 30

According to the companies, the deal has the potential to result in new patient friendly cancer treatments that could be a significant step towards personalized medicine. As part

The validation of MAA confirms that the submission is complete and signifies the start of the review process by the EMA’s Committee for Medicinal Products for Human Use

WuXi MedImmune Biopharmaceutical is a joint venture (JV) formed in September 2012 by AstraZeneca’s global biologics research and development arm MedImmune, and WuXi AppTec. The JV was created

In May last year, the company submitted a NDA to the FDA pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act, as amended, for approval of